A permutation test approach to phase II historical control trials

References

• Alberts , D. S. 1996 . Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer . N. Engl. J. Med. , 335 : 1950 – 1955 .
   PubMed Web of Science ®Google Scholar
• Armstrong , D. K. , Bundy , B. N. Baergen , R. 2002 . Randomized phase III study of intravenous (IV) paclitaxel and cisplatin versus IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 172) . Proc. Am. Soc. Clin. Oncol , 21 : 201a
   Web of Science ®Google Scholar
• Berek , J. S. , Markman , M. , Blessing , J. A. , Kucera , P. R. , Nelson , B. E. , Anderson , B. and Hanjani , P. 1999 . Intraperitoneal α-interferon alternating with cisplatin in residual ovarian carcinoma: a phase II Gynecologic Oncology Group trial . Gynecol. Oncol. , 74 : 48 – 52 .
   PubMed Web of Science ®Google Scholar
• Berek , J. S. , Markman , M. , Stonebreaker , B. , Lentz , S. S. , Adelson , M. D. , DeGeest , K. and Moore , D. 1999 . Intraperitoneal interferon-α in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study . Gynecol. Oncol. , 75 : 10 – 14 .
   PubMed Web of Science ®Google Scholar
• Braly , P. S. , Berek , J. S. , Blessing , J. A. , Homesley , H. D. and Averette , H. 1995 . Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: a phase II Gynecologic Oncology Group trial . Gynecol. Oncol. , 56 : 164 – 168 .
   PubMed Web of Science ®Google Scholar
• Cannistra , S. A. 2004 . Cancer of the Ovary . N. Engl. J. Med. , 351 : 2519 – 2529 .
   PubMed Web of Science ®Google Scholar
• D'Agostino , R. B. 1998 . Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group . Stat. Med , 17 : 2265 – 2281 .
   PubMed Web of Science ®Google Scholar
• Feun , L. G. , Blessing , J. A. , Major , F. J. , DiSaia , P. J. , Alvarez , R. D. and Berek , J. S. 1998 . A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study . Gynecol. Oncol. , 71 : 410 – 415 .
   PubMed Web of Science ®Google Scholar
• Francis , P. , Rowinsky , E. , Schneider , J. , Hakes , T. , Hoskins , W. and Markman , M. 1995 . Phase 1 feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot study . J. Clin. Oncol. , 13 : 2961 – 2967 .
   PubMed Web of Science ®Google Scholar
• Lehmann , E. L. 1986 . Testing Statistical Hypotheses , California : Wadsworth & Brooks/Cole, Pacific Grove .
   Google Scholar
• Makuch , R. W. and Simon , R. M. 1980 . Sample size considerations for non-randomized comparative studies . J. Chronic Disease , 33 : 175 – 181 .
   PubMedGoogle Scholar
• Markman , M. 1999 . Intraperitoneal chemotherapy . Crit. Rev. Oncol. Hematol , 31 : 239 – 246 .
   PubMed Web of Science ®Google Scholar
• Markman , M. 2003 . Intraperitoneal antineoplastic drug delivery: rational and results . Lancet Oncol , 4 : 277 – 283 .
   PubMed Web of Science ®Google Scholar
• Markman , M. , Berek , J. B. , Blessing , J. , McGuire , W. P. , Bell , J. and Homesley , H. D. 1992 . Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based IP chemotherapy: lessons learned from a Gynecologic Oncology Group phase II trial of IP cisplatin and recombinant alpha-interferon . Gynecol. Oncol. , 45 : 3 – 8 .
   PubMed Web of Science ®Google Scholar
• Markman , M. 1992 . Phase I trial of intraperitoneal taxol - a Gynecologic Oncology Group study (1992) . J. Clin. Oncol. , 10 : 1485 – 1491 .
   PubMed Web of Science ®Google Scholar
• Markman , M. , Blessing , J. A. , Major , F. and Manetta , A. 1998 . Salvage intraperitoneal therapy of ovarian cancer employing cisplatin and etoposide: a Gynecologic Oncology Group study . Gynecol. Oncol. , 50 : 191 – 195 .
   Web of Science ®Google Scholar
• Markman , M. , Brady , M. F. , Spirtos , N. M. , Hanjani , P. and Rubin , S. C. 1998 . Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group study . J. Clin. Oncol. , 16 : 2620 – 2624 .
   PubMed Web of Science ®Google Scholar
• Markman , M. , Bundy , B. N. , Alberts , D. S. , Fowler , J. M. , Clark-Pearson , D. L. , Carson , L. F. , Wadler , S. and Sickel , J. 2001 . Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology group, Southwestern Oncology group, and Eastern cooperative Oncology Group . J. Clin. Oncol. , 19 : 1001 – 1007 .
   PubMed Web of Science ®Google Scholar
• Rosenbaum , P. R. 2002 . Covariance adjustment in randomized experiments and observational studies . Stat. Sci , 17 : 286 – 304 .
   Web of Science ®Google Scholar